The research focused on the pathophysiology of migraine lead to the discovery of the key role that anti-calcitonin gene-related peptide (CGRP) play in its etiopathogenesis and to the development of new drugs. Anti-CGRP mabs are highly effective for the prevention of migraine and represent a promising new solution for patients and their physicians.
eptinezumab from Lundbeck; erenumab from Amgen; fremanezumab from Teva Pharmaceuticals and galcanezumab from Eli Lilly and Company are among these Anti-CGRP mabs approved by the #FDA
Are you involved in R&D on antibodies ?
Are you planning to screen different protein variants?
👉 We at Magellan Biologics & Consulting proudly support the scientific community in their R&D projects through our CHO4Tx® product portfolio that allows in-house, fast, easy and efficient transient protein expression in CHO cells and through personalized advices and consultancies.
